Innate Pharma (IPHA) Total Liabilities (2017 - 2019)

Innate Pharma (IPHA) has disclosed Total Liabilities for 3 consecutive years, with $203.6 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Total Liabilities fell 37.18% year-over-year to $203.6 million, compared with a TTM value of $203.6 million through Dec 2019, down 37.18%, and an annual FY2019 reading of $206.0 million, down 38.59% over the prior year.
  • Total Liabilities was $203.6 million for Q4 2019 at Innate Pharma, down from $324.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $324.1 million in Q4 2018 and bottomed at $199.1 million in Q4 2017.
  • Average Total Liabilities over 3 years is $242.3 million, with a median of $203.6 million recorded in 2019.
  • The sharpest move saw Total Liabilities skyrocketed 62.83% in 2018, then crashed 37.18% in 2019.
  • Year by year, Total Liabilities stood at $199.1 million in 2017, then surged by 62.83% to $324.1 million in 2018, then plummeted by 37.18% to $203.6 million in 2019.
  • Business Quant data shows Total Liabilities for IPHA at $203.6 million in Q4 2019, $324.1 million in Q4 2018, and $199.1 million in Q4 2017.